Corcept Therapeutics Incorporated (BIT:1CORT)

Market Cap	7.22B
Revenue (ttm)	609.74M
Net Income (ttm)	112.41M
Shares Out	n/a
EPS (ttm)	0.95
PE Ratio	64.26
Forward PE	56.23
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	13
Open	67.60
Previous Close	66.32
Day's Range	67.20 - 67.60
52-Week Range	57.62 - 71.34
Beta	n/a
RSI	66.12
Earnings Date	Oct 29, 2025

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical t...

• Industry: Pharmaceutical Preparations
• Founded: 1998
• Employees: 500
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1CORT

Financial Performance

In 2024, Corcept Therapeutics's revenue was $675.04 million, an increase of 39.94% compared to the previous year's $482.38 million. Earnings were $139.73 million, an increase of 32.45%.

Financial numbers in USD